The Endocannabinoid System as a Therapeutic Target in Glaucoma

Elizabeth A. Cairns, William H. Baldridge, Melanie E.M. Kelly

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

59 Citas (Scopus)

Resumen

Glaucoma is an irreversible blinding eye disease which produces progressive retinal ganglion cell (RGC) loss. Intraocular pressure (IOP) is currently the only modifiable risk factor, and lowering IOP results in reduced risk of progression of the disorder. The endocannabinoid system (ECS) has attracted considerable attention as a potential target for the treatment of glaucoma, largely due to the observed IOP lowering effects seen after administration of exogenous cannabinoids. However, recent evidence has suggested that modulation of the ECS may also be neuroprotective. This paper will review the use of cannabinoids in glaucoma, presenting pertinent information regarding the pathophysiology of glaucoma and how alterations in cannabinoid signalling may contribute to glaucoma pathology. Additionally, the mechanisms and potential for the use of cannabinoids and other novel agents that target the endocannabinoid system in the treatment of glaucoma will be discussed.

Idioma originalEnglish
Número de artículo9364091
PublicaciónNeural Plasticity
Volumen2016
DOI
EstadoPublished - 2016

Nota bibliográfica

Funding Information:
The writing of this review was supported by a grant from the Canadian Institutes of Health Research (CIHR) MOP-97768 (Melanie E. M. Kelly).

Publisher Copyright:
© 2016 Elizabeth A. Cairns et al.

ASJC Scopus Subject Areas

  • Neurology
  • Clinical Neurology

Huella

Profundice en los temas de investigación de 'The Endocannabinoid System as a Therapeutic Target in Glaucoma'. En conjunto forman una huella única.

Citar esto